title: Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
abstract: OBJECTIVE
  Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).
  
  
  RESULTS
  Patients with ACS (n = 241) or high-risk CAD (n = 263) received E5555 (50, 100, or 200 mg) or placebo once daily for 12 (ACS patients) or 24 weeks (CAD patients). The incidence of TIMI major, minor, and minimal bleeds requiring medical attention was similar in the placebo and combined E5555 (atopaxar) groups (ACS: 6.6% placebo vs. 5.0% E5555; CAD: 1.5% placebo vs. 1.5% E5555). There were no TIMI major bleeds and three CURE major bleeds (two with placebo; one with 100 mg E5555). There was a numerical increase in 'any' TIMI bleeding with the E5555 200 mg dose (ACS: 16.4% placebo vs. 23.0% E5555, P = 0.398; CAD: 4.5% placebo vs. 13.2% E5555, P = 0.081). The rate of major cardiovascular adverse events in the combined E5555 group was not different from placebo (ACS: 6.6% placebo vs. 5.0% E5555, P = 0.73; CAD: 4.5% placebo vs. 1.0% E5555, P = 0.066). There was a statistically significant dose-dependent increase in liver function abnormalities and QTcF with E5555. At trough dosing levels in both populations, mean inhibition of platelet aggregation was > 90% with 100 and 200 mg E5555, and 20-60% with 50 mg E5555.
  
  
  CONCLUSIONS
  E5555 (50, 100, and 200 mg) did not increase clinically significant bleeding, although there was a higher rate of any TIMI bleeding with the highest two doses. All doses tested achieved a significant level of platelet inhibition. There was a significant dose-dependent increase in liver function abnormalities and QTcF. Although further study is needed, PAR-1 antagonism may have the potential to be a novel pathway for platelet inhibition to add on to the current standard of care therapy.
authors.affiliation: Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Kanagawa 259-1143, Japan. shinichi@is.icc.u-tokai.ac.jp
authors.forename: Shinya
authors.initials: S
authors.lastname: Goto
authors.forename: Hisao
authors.initials: H
authors.lastname: Ogawa
authors.forename: Masaru
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Marcus D
authors.initials: MD
authors.lastname: Flather
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000284:Administration, Oral; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007097:Imines / Q000008:administration & dosage*; D008133:Long QT Syndrome / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*
chemical_list: C540445:E 5555; D007097:Imines; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines
references.citation: N Engl J Med. 2001 Aug 16;345(7):494-502
references.pmid: 11519503
references.citation: Am J Cardiol. 2009 Feb 2;103(3 Suppl):4A-10A
references.pmid: 19166707
references.citation: Eur Heart J. 2010 Jan;31(1):17-28
references.pmid: 19948715
references.citation: Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):149-56
references.pmid: 15320797
references.citation: Expert Opin Ther Pat. 2006 Apr;16(4):493-505
references.pmid: 20144050
references.citation: Ann Intern Med. 1991 Aug 15;115(4):256-65
references.pmid: 1906692
references.citation: Stroke. 2003 Oct;34(10):2349-54
references.pmid: 12958323
references.citation: Circ J. 2007 Jul;71(7):995-1003
references.pmid: 17587702
references.citation: Eur Heart J. 2000 Dec;21(24):2033-41
references.pmid: 11102254
references.citation: Lancet. 2009 Mar 14;373(9667):919-28
references.pmid: 19286091
references.citation: Thromb Haemost. 2009 Jul;102(1):111-9
references.pmid: 19572075
references.citation: Nature. 2000 Sep 14;407(6801):258-64
references.pmid: 11001069
references.citation: Blood Rev. 2009 Mar;23(2):61-5
references.pmid: 18644663
references.citation: Circulation. 2000 Mar 14;101(10):1206-18
references.pmid: 10715270
references.citation: J Thromb Haemost. 2005 Oct;3(10):2315-23
references.pmid: 16194207
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: JAMA. 2006 Jan 11;295(2):180-9
references.pmid: 16403930
references.citation: N Engl J Med. 2009 Sep 10;361(11):1045-57
references.pmid: 19717846
references.citation: J Atheroscler Thromb. 2010 Feb 26;17(2):156-64
references.pmid: 20124733
references.citation: N Engl J Med. 2007 Nov 15;357(20):2078-81
references.pmid: 17982183
references.citation: Circ J. 2005 Jul;69(7):767-73
references.pmid: 15988100
references.citation: J Thromb Haemost. 2006 Jan;4(1):114-20
references.pmid: 16409460
references.citation: Thromb Res. 2010 Mar;125(3):257-61
references.pmid: 19476974
references.citation: Circ Res. 2007 May 11;100(9):1261-75
references.pmid: 17495233
references.citation: Circulation. 2006 May 16;113(19):2363-72
references.pmid: 16702489
references.citation: Circulation. 2007 Aug 14;116(7):e148-304
references.pmid: 17679616
references.citation: N Engl J Med. 2007 Nov 15;357(20):2001-15
references.pmid: 17982182
references.citation: Hepatology. 2004 Feb;39(2):574-8
references.pmid: 14768020
references.citation: JAMA. 2007 Mar 21;297(11):1197-206
references.pmid: 17374814
references.citation: J Invasive Cardiol. 2003 Mar;15 Suppl B:3B-9B; discussion 9B-10B
references.pmid: 12724580